The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
Tejedor Vaquero, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques)
de Campos-Mata, Leire (Institut Hospital del Mar d'Investigacions Mèdiques)
Ramada, José María (CIBER de Epidemiología Y Salud Pública)
Díaz, Pilar (Institut Hospital del Mar d'Investigacions Mèdiques)
Navarro-Barriuso, Juan (Institut Hospital del Mar d'Investigacions Mèdiques)
Ribas-Llaurado, Clara (Institut Hospital del Mar d'Investigacions Mèdiques)
Rodrigo Melero, Natalia (Centre de Regulació Genòmica)
Carolis, Carlo (Universitat Pompeu Fabra)
Cerutti, Andrea (Institució Catalana de Recerca i Estudis Avançats)
Gimeno Martínez, Ramón (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Magri, Giuliana (Institut Hospital del Mar d'Investigacions Mèdiques)

Date:	2021
Abstract:	mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Humoral immunity ; Antibody subclasses ; COVID-19 ; Variants of concern ; Mrna vaccination
Published in:	Frontiers in immunology, Vol. 12 (September 2021) , art. 737083, ISSN 1664-3224

DOI: 10.3389/fimmu.2021.737083
PMID: 34539673

9 p, 1.2 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles